DARE Stock Dare Bioscience (DARE, $3.3) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 26, 2024

GET DAILY SIGNALS

Get AI intraday signals

DARE - Dare Bioscience Inc.

MACD signal

View

Odds of UP Trend

Price: $3.3

Daily change: +$0.1 (+3.13%)

Daily volume: 22.2K

Capitalization: $28.7M

Industry: Biotechnology

DARE saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for DARE moved out of overbought territory on January 10, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In of the 49 cases the stock moved lower. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DARE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for DARE entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DARE's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 13, 2025. You may want to consider a long position or call options on DARE as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DARE just turned positive on December 26, 2024. Looking at past instances where DARE's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DARE advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

DARE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.267) is normal, around the industry mean (15.339). P/E Ratio (0.099) is within average values for comparable stocks, (87.552). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.851). DARE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (14.793) is also within normal values, averaging (263.778).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.